Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moss GenomicsFRA:F73 Current Ratio is 7.45 as of Mar. 2026, which is 280% above its 10-year median of 1.96. Among 681 Healthcare Providers & Services companies, Moss Genomics ranks better than 93.39% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Moss Genomics's current ratio for the quarter that ended in Mar. 2026 was 7.45.
Moss Genomics has a current ratio of 7.45. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Moss Genomics's Current Ratio or its related term are showing as below:
FRA:F73'
s Current Ratio Range Over the Past 10 Years
Min: 0.32 Med: 1.96 Max: 15.29
Current: 7.47
During the past 4 years, Moss Genomics's highest Current Ratio was 15.29. The lowest was 0.32. And the median was 1.96.
FRA:F73's Current Ratio is ranked better than 93.39% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 1.47
vs FRA:F73: 7.47
Moss Genomics (FRA:F73) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Moss Genomics Current Ratio Related Terms
Moss Genomics Current Ratio Historical Data
* Premium members only.
The historical data trend for Moss Genomics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F73 vs VEEV, BTSG, TEM: Current Ratio Comparison
For the Health Information Services subindustry, Moss Genomics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moss Genomics Current Ratio vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Moss Genomics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Moss Genomics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moss Genomics (FRA:F73) has a Current Ratio of 7.45 as of Mar. 2026. This is 280% above median its historical median of 1.96. Over the past decade, Moss Genomics' Current Ratio has ranged from 0.32 to 15.29. According to the industry distribution chart, Moss Genomics ranks #45 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 6.6%.
Is Moss Genomics' Current Ratio too high?
Moss Genomics' current Current Ratio of 7.45 is 280% above median its 10-year median of 1.96. Over the past 10 years, this metric has ranged from a low of 0.32 to a high of 15.29. The Healthcare Providers & Services industry median Current Ratio is 1.47. Moss Genomics' value of 7.45 is 406.8% above this industry median. Based on the distribution chart, Moss Genomics ranks #45 out of 681 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers.
How does Moss Genomics' Current Ratio compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Moss Genomics ranks #45 out of 681 companies for Current Ratio. This places Moss Genomics in the top 7% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.47. Moss Genomics' value of 7.45 is 406.8% above this benchmark. Historically, Moss Genomics' own Current Ratio has ranged from 0.32 to 15.29 over the past decade. While the company's 10-year median is 1.96 vs. the industry median of 1.47, Moss Genomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Healthcare Providers & Services company?
The median Current Ratio among Healthcare Providers & Services companies is 1.47, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moss Genomics's current Current Ratio of 7.45 is 406.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Healthcare Providers & Services industry, the median Current Ratio is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moss Genomics's current Current Ratio is 7.45, which is 280% above median its own 10-year median of 1.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moss Genomics stock overvalued right now?
Moss Genomics (FRA:F73) has a current Current Ratio of 7.45. The current Current Ratio is 7.45, which is 280% above median its 10-year median of 1.96 and 406.8% above the Healthcare Providers & Services industry median of 1.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Moss Genomics (FRA:F73), the current Current Ratio is 7.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Moss Genomics Inc is an emerging consumer genomics company that provides personalized health, anti-aging, and wellness solutions based on genomic, microbiome, and epigenome data. It aims to eliminate barriers in healthcare by offering accessible, affordable at-home testing along with easy-to-understand actionable results.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F73 has been successfully added to your 
